Form 8-K Amphastar Pharmaceutical For: Mar 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amphastar Pharma (AMPH) Tops Q4 EPS by 23c
March 14, 2016 4:21 PM EDTAmphastar Pharma (NASDAQ: AMPH) reported Q4 EPS of $0.19, $0.23 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $76.9 million versus the consensus estimate of $64.48 million.
For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.
... More